Evidence map›Paper›PMID 40140673›Full record

ArticleTranslational psychiatry2025

A hyper-activatable CAMK2A variant associated with intellectual disability causes exaggerated long-term potentiation and learning impairments.

Miao Pan, Pin-Wu Liu, Yukihiro Ozawa, Fumiko Arima-Yoshida, Geyao Dong, Masahito Sawahata, Daisuke Mori, Masashi Nagase, Hajime Fujii, Shuhei Ueda and 13 more

Abstract read
In one paragraph

Article in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Miao PanDepartment of Neuroscience, Research Institute of Environmental Medicine, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, Japan.
Pin-Wu Liu *Department of Neuroscience, Research Institute of Environmental Medicine, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0001-8053-2098
Yukihiro Ozawa *Department of Neuroscience, Research Institute of Environmental Medicine, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, Japan.
Fumiko Arima-YoshidaInstitute of Clinical Medicine and Research, Research Center for Medical Sciences, The Jikei University School of Medicine, 163-1 Kashiwashita, Kashiwa, Chiba, Japan.
Geyao DongDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan.
Masahito SawahataDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan.
Daisuke MoriDepartment of Pathophysiology of Mental Disorders, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0002-9072-2546
Masashi NagaseInstitute of Clinical Medicine and Research, Research Center for Medical Sciences, The Jikei University School of Medicine, 163-1 Kashiwashita, Kashiwa, Chiba, Japan.
Hajime FujiiDepartment of Neurochemistry, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan.
Shuhei UedaDepartment of Neuroscience, Research Institute of Environmental Medicine, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0001-8107-8608
Yurie YabuuchiDepartment of Neuroscience, Research Institute of Environmental Medicine, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, Japan.
Xinzi LiuDepartment of Neuroscience, Research Institute of Environmental Medicine, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, Japan.
Hajime NaritaDepartment of Neuroscience, Research Institute of Environmental Medicine, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, Japan.ORCID http://orcid.org/0009-0000-1414-7802
Ayumu KonnoDepartment of Neurophysiology & Neural Repair, Gunma University Graduate School of Medicine, 3-39-33 Showa-machi, Maebashi, Gunma, Japan.ORCID http://orcid.org/0000-0001-9382-396X
Hirokazu HiraiDepartment of Neurophysiology & Neural Repair, Gunma University Graduate School of Medicine, 3-39-33 Showa-machi, Maebashi, Gunma, Japan.
Norio OzakiDepartment of Pathophysiology of Mental Disorders, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan.
Kiyofumi YamadaDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan.ORCID http://orcid.org/0000-0002-5280-5180
Hiroyuki KidokoroDepartment of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan.
Haruhiko BitoDepartment of Neurochemistry, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan.ORCID http://orcid.org/0000-0001-6315-9594
Hiroyuki MizoguchiDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan.
Ayako M WatabeInstitute of Clinical Medicine and Research, Research Center for Medical Sciences, The Jikei University School of Medicine, 163-1 Kashiwashita, Kashiwa, Chiba, Japan.
Shin-Ichiro HoriganeDepartment of Neuroscience, Research Institute of Environmental Medicine, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, Japan.
Sayaka Takemoto-KimuraDepartment of Neuroscience, Research Institute of Environmental Medicine, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, Japan. stakemoto@riem.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0002-2190-3191

Funding

Japan Agency for Medical Research and Development (AMED) 23jm0210098Japan Agency for Medical Research and Development (AMED) JP21dm0207111MEXT | Japan Society for the Promotion of Science (JSPS) JP20H03339MEXT | Japan Society for the Promotion of Science (JSPS) JP22K06454MEXT | Japan Society for the Promotion of Science (JSPS) JP22K15638MEXT | Japan Society for the Promotion of Science (JSPS) JP23H02795MEXT | Japan Society for the Promotion of Science (JSPS) JP23K17639MEXT | Japan Society for the Promotion of Science (JSPS) JP23K27486MEXT | Japan Society for the Promotion of Science (JSPS) JP24H01221MEXT | Japan Society for the Promotion of Science (JSPS) JP24K10490
6 · The paper itself

Abstract

Intellectual disability (ID) is a neurodevelopmental disorder (NDD) characterized by impairments in intellectual and adaptive functioning, and is highly co-morbid with other NDDs. Recently, de novo missense variants in the gene, CAMK2A, which encodes calcium/calmodulin-dependent protein kinase IIα (CaMKIIα), an abundant neuronal protein crucial for synaptic plasticity, learning and memory, have been implicated in ID. However, the causative impact of these mutations remains underexplored. In this study, we developed a heterozygous knock-in mouse model carrying the most prevalent ID-associated CAMK2A de novo missense variant, P212L, as a gain-of-function allele. The knock-in mice exhibited increased autophosphorylation of CaMKIIα, indicative of exuberant kinase activity, and consistently showed dendritic spine abnormalities and exaggerated hippocampal long-term potentiation induced by a subthreshold low-frequency stimulation. Furthermore, a comprehensive behavioral evaluation, including learning and memory tasks, revealed prominent phenotypes recapitulating the complex clinical phenotypes of humans with ID/NDDs harboring the same variant. Taken together, we propose that aberrant enhancement of CaMKIIα signaling by the heterozygous P212L mutation underlies a subset of ID/NDD features. These findings provide new insights into the pathogenesis of ID/NDDs, specifically through the genetic up-shifting of the critical memory regulator, CaMKII. Additionally, the established mouse model, with both construct and face validity, is expected to significantly contribute to the understanding and future therapeutic development of ID/NDDs.

Indexed as

Calcium-Calmodulin-Dependent Protein Kinase Type 2Intellectual DisabilityLearning DisabilitiesLong-Term PotentiationAnimalsDendritic SpinesDisease Models, AnimalGene Knock-In TechniquesHippocampusMaleMiceMutation, MissenseCalcium-Calmodulin-Dependent Protein Kinase Type 2Camk2a protein, mouse

Identifiers

PMID40140673
PMCPMC11947108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.